文献速递胸部肿瘤

肠道微生物组多样性与中国非小细胞肺癌患者抗程序性死亡受体1免疫治疗有利应答相关

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-04-23

研究纳入37例接受纳武利尤单抗治疗的晚期非小细胞肺癌中国患者,采用16S核糖体RNA基因测序分析粪便微生物组,并按RECIST 1.1分为应答者与非应答者。应答者基线肠道微生物组多样性更高且治疗期间组成稳定,高多样性患者无进展生存期显著延长,且外周记忆CD8+ T细胞和自然杀伤细胞亚群频率更高。

要点

  • 应答者基线肠道微生物组多样性更高,治疗期间组成稳定。
  • 高微生物组多样性患者较低多样性患者无进展生存期显著延长。
  • 应答者富集Alistipes putredinis、Bifidobacterium longum和Prevotella copri。

核心结论

  • 中国晚期非小细胞肺癌患者肠道微生物组多样性与抗PD-1免疫治疗应答之间存在强相关性。
  • 肠道微生物组良好(如高多样性)的患者外周记忆T细胞和自然杀伤细胞特征增强。

研究设计与样本

  • 研究纳入37例接受纳武利尤单抗治疗的晚期非小细胞肺癌患者,来自CheckMate 078(NCT02613507)和CheckMate 870(NCT03195491)。
  • 在开始纳武利尤单抗治疗时、临床评估时和疾病进展时采集粪便样本,采用16S核糖体RNA基因测序评估肠道微生物组谱。
  • 同时采用多色流式细胞术检测外周免疫特征。
  • 根据实体瘤疗效评价标准1.1版评估临床应答,将患者分为应答者(R)和非应答者。

主要发现

  • 应答者基线肠道微生物组多样性更高,且治疗期间组成稳定。
  • 高微生物组多样性患者较低多样性患者无进展生存期显著延长。
  • 应答者中Alistipes putredinis、Bifidobacterium longum和Prevotella copri富集,非应答者中Ruminococcus_unclassified富集。
  • 多色流式细胞术分析显示,肠道微生物组高多样性患者外周血中独特记忆CD8+ T细胞和自然杀伤细胞亚群频率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Gut microbiome affecting the responses to immune checkpoint inhibitors against advanced NSCLC has been investigated in the Western population. However, considering pre-existing genetic and gut microbiota variation, the relevance remains unknown in the East-Asian NSCLC population. This study is designed to explore the relationship between gut microbiome and clinical outcomes in Chinese patients with NSCLC who have received treatment using an anti-programmed death 1 (PD-1) blockade. METHODS: Thirty-seven patients with advanced NSCLC receiving treatment with nivolumab were enrolled in CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, when patients received nivolumab, at clinical evaluation, and when disease progression was noted. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multicolor flow cytometry in parallel. RESULTS: When subgrouping patients into responder (R) and nonresponder according to the clinical response assessed using Response Evaluation Criteria in Solid Tumor version 1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival when compared to those with low diversity. Compositional difference was observed between the two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, and Prevotella copri in R whereas Ruminococcus_unclassified enriched in nonresponding patients. Analysis of systemic immune responses using multicolor flow cytometry revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8+ T cell and natural killer cell subsets in the periphery in response to anti-PD-1 therapy. CONCLUSIONS: Our results reveal strong correlation between gut microbiome diversity and the responses to anti-PD-1 immunotherapy in Chinese patients with advanced NSCLC. Patients with favorable gut microbiome (such as those with high diversity) exhibit enhanced memory T cell and natural killer cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti-PD-1 immunotherapy against NSCLC in the Chinese population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Jin Y, Dong H, Xia L, et al. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. J Thorac Oncol. 2019. PMID: 31026576. doi:10.1016/j.jtho.2019.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。